文献速递支持与姑息治疗

早期删失率高的试验中健康相关生活质量数据的解读:应谨慎对待

Health-related quality of life in trials with high rates of early censoring: Caution advised.
PubMed 文献 · Eur J Cancer · 2024-05-06

该文讨论随机试验中健康相关生活质量(HRQoL)数据分析的关键考量——问卷完成率。当某一治疗组完成率过低时,未完成问卷的患者可能因毒性更大而HRQoL更差;若采用完整病例分析,可能遗漏HRQoL的下降。作者指出,在无进展生存或总生存终点存在高且不平衡的早期删失率时,HRQoL结果仅适用于仍在试验中的患者亚群,应谨慎解读,并应先探究主要时间-事件分析中的删失原因。

要点

  • HRQoL分析中,某一治疗组问卷完成率过低可能反映未完成问卷者因毒性导致HRQoL更差。
  • 完整病例分析可能遗漏HRQoL的下降,尤其当低完成率出现在毒性更大的治疗组时。
  • 在高且不平衡的早期删失率影响PFS或OS的试验中,HRQoL结果应谨慎解读,并先探究删失原因。

核心结论

  • 在PFS或OS终点存在高且不平衡的早期删失率的试验中,HRQoL结果应谨慎解读,并应先探究主要时间-事件分析中的删失原因,再对HRQoL做出确定结论。
  • 在非劣效设计试验中,若HRQoL获益被用作改变实践的 justification,上述谨慎解读更为重要。

研究设计与样本

  • 本文为方法学讨论文章,未报告系统检索范围或原始研究数据。

主要发现

  • 当某一治疗组问卷完成率过低时,未完成问卷的患者可能因毒性更大而HRQoL更差。
  • 若采用完整病例分析,可能遗漏HRQoL的下降。
  • 完成率高时HRQoL数据被认为更可靠,信息性删失可能性更低,但作者指出这种推理可能不充分。
  • 在高且不平衡的早期删失率影响PFS或OS终点的试验中,完成率仅适用于仍在试验中的患者亚群。

临床怎么用

  • 原文未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Health-related quality-of-life (HRQoL) data are central to capturing the quality of patients' life, while endpoints like overall survival (OS) focus on the quantity of life. When analyzing HRQoL data gathered from patients in a randomized trial, a key consideration is the completion rate - indicating the proportion of patients remaining in the trial and with completed questionnaires. When completion rates are disproportionately low in one treatment arm, one likely explanation is that patients who did not complete questionnaires suffered more from toxicities, negatively impacting their HRQoL. This is likely the case when low completion rates occur in the more toxic arm within a randomized trial. If the HRQoL analysis is run as a complete-case analysis - only considering patients without missing data - a decrement in HRQoL can be missed. Conversely, when completion rates are high, the HRQoL data are thought to be more reliable, and informative censoring is less likely. We describe why this reasoning can be inadequate. In trials where high and imbalanced rates of early censoring affect progression-free survival or OS endpoints, the completion rates only apply to the fraction of patients remaining in the trial. In those, HRQoL results should be considered with caution, and reasons for censoring in the primary time-to-event analyses should be explored before making definite conclusions about HRQoL. This is even more relevant in trials with non-inferiority design, where a benefit in HRQoL could be used as a justification to modify practice.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Olivier T, Haslam A, Prasad V, et al. Health-related quality of life in trials with high rates of early censoring: Caution advised. Eur J Cancer. 2024. PMID: 38718724. doi:10.1016/j.ejca.2024.114105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。